WO2025168048 - COMPOUND HAVING TRIPLE BOND STRUCTURE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/168048
Publication Date
14.08.2025
International Application No.
PCT/CN2025/076194
International Filing Date
07.02.2025
Title **
[English]
COMPOUND HAVING TRIPLE BOND STRUCTURE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
[French]
COMPOSÉ AYANT UNE STRUCTURE À TRIPLE LIAISON, ET COMPOSITION PHARMACEUTIQUE ASSOCIÉE ET UTILISATION ASSOCIÉE
[Chinese]
一种三键结构化合物、其药物组合物及其应用
Applicants **
SHANGHAI YINGLI PHARMACEUTICAL CO., LTD
Inventors
XU, Zusheng
XIA, Lin
Priority Data
202410177107.7
08.02.2024
CN
202410884577.7
03.07.2024
CN
202411908314.1
24.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2559 | |
| EPO | Filing, Examination, Granting | 15052 | |
| Japan | Filing, Examination, Granting | 2024 | |
| South Korea | Filing, Examination, Granting | 1848 | |
| USA | Filing, Examination, Granting | 5190 |
Total:
26,673
Contact Us
Abstract[English]
Disclosed in the present invention are a compound having a triple bond structure, and a pharmaceutical composition thereof and the use thereof. Provided in the present invention is a compound having a triple bond structure as represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof, a crystal form thereof, a stereoisomer thereof, a tautomer thereof, or an isotope compound thereof. As a highly selective inhibitor, the compound having the triple bond structure of the present invention can not only meet the requirements of tumor treatment, but also helps to reduce adverse reactions caused by the inhibition of PARP-2.[French]
La présente invention concerne un composé ayant une structure à triple liaison, et une composition pharmaceutique associée et l'utilisation associée. La présente invention concerne un composé ayant une structure à triple liaison telle que représentée par la formule I, un sel pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, un solvate du sel pharmaceutiquement acceptable de celui-ci, une forme cristalline de celui-ci, un stéréoisomère de celui-ci, un tautomère de celui-ci, ou un composé isotope de celui-ci. En tant qu'inhibiteur hautement sélectif, le composé ayant la structure à triple liaison de la présente invention peut non seulement satisfaire aux exigences d'un traitement de tumeur, mais aide également à réduire des réactions néfastes provoquées par l'inhibition de PARP-2.[Chinese]
本发明公开了一种三键结构化合物、其药物组合物及其应用。本发明提供了一种如式I所示的三键结构化合物、其药学上可接受的盐、其溶剂合物、其药学上可接受的盐的溶剂合物、其晶型、其立体异构体、其互变异构体或其同位素化合物。本发明的三键结构化合物作为高选择性抑制剂不仅能够满足肿瘤治疗的要求，而且有助于减少对PARP-2抑制而产生的不良反应。